As a result of this ruling, the patent protection for this product is maintained in the US until November 2011.
Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from Apotex, in reparation of harm caused by that company’s marketing and sale of an infringing generic version of Plavix in 2006.